VX-828

VX-828 is an investigational small molecule drug developed by Vertex Pharmaceuticals for the treatment of cystic fibrosis. It is administered orally, typically as a suspension, and is currently in Phase 1 clinical trials in the United States. VX-828 targets the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which plays a key role in regulating salt and water transport across cell membranes—a process disrupted in cystic fibrosis patients. The precise mechanism of action has not been fully defined or disclosed publicly, but it is being evaluated both as a monotherapy and in combination with other CFTR modulators such as tezacaftor (TEZ) and VX-118[1][2][4][5][7].